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A mutation conferring aurovertin resistance on Escherichia coli F 1 -ATPase was identified as R398---, H in the F 1 fl-subunit. 
fl-subunit from the mutant does not bind aurovertin; therefore our results uggest the region of sequence around residue 
]/-398 is involved in aurovertin binding. Since nucleotide and aurovertin binding to isolated fl-subunit are not mutually 
exclusive, the data further suggest that he fl-subunit catalytic nucleotide-binding domain does not include residue 398. 
The mutation prevented aurovertin hibition of ATPase at pH 6 and 8.5, implying charge on the arginine side-chain 
is not a major determinant of aurovertin binding or that the pK of R398 is shifted ue to a peculiar environment. The 
equivalent residue isusually arginine in F1 fl-subunits of different species; notably in the aurovertin-insensitive thermo- 
philic bacterium PS3 F~-ATPase, this residue isphenylalanine. 
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1. INTRODUCTION 
Aurovertin is an antibiotic that inhibits ox- 
idative phosphorylation by binding tightly and 
specifically to the/~-subunit of F~-ATPases [1,2]. 
In Escherichia coli aurovertin inhibits growth of 
cells on nonfermentable substrates [3], it inhibits 
the activity of purified soluble F~ with 50°70 inhibi- 
tion occurring at -1/zM,  and it binds with Ku 
3-6/zM to isolated F1/5'-subunit [4,5]. 
Aurovertin has proved to be a useful probe of 
conformational changes and catalytic mechanism 
of F1-ATPases, for the reason that it fluoresces 
when bound to the enzyme. Chang and Penefsky 
[6] used the antibiotic to demonstrate r spiration- 
induced conformational changes of F~-ATPase in 
submitochondrial particles, experiments which we 
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can now interpret as a demonstration of trans- 
membrane A/zH+-induced conformational change 
of the aurovertin-binding site on fl-subunit of 
F~-ATPase. Later, Wise and colleagues [7] used 
aurovertin-fluorescence measurements to demon- 
strate that some mutations in ce-subunit of E. coli 
F~-ATPase block a/Ct-intersubunit conformational 
interactions. They proposed that such interactions 
were an integral part of the catalytic mechanism. 
Several other important studies utilizing aurovertin 
as a fluorescent probe could be cited (e.g. [8,9]). 
It would therefore be valuable to know where 
the binding site for aurovertin is on F~ ~'-subunit. 
Satre et al. [3,10] isolated aurovertin-resistant 
mutants of E. coli and demonstrated that the 
mutations mapped in the region of the unc operon. 
One of the mutations (in strain MA12) was ex- 
amined in some detail and shown to confer 
aurovertin resistance to F1-ATPase. Further, 
aurovertin resistance was shown to be due to a 
mutation in F1 fl-subunit by in vitro subunit 
dissociation-reassociation experiments, and 
isolated/~-subunit from MA12 was shown not to 
bind aurovertin [4]. Here we have identified the 
mutation in MA12/Y-subunit. 
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2. MATERIALS  AND METHODS 
2.1. General 
All molecular biology methods were as previously described 
[11,12] except where noted below. Strains of E. coli were as 
follows: MA12, aurovertin-resistant mutant strain [3,10]; 
AN818 [11], JM109 [13], AN1339 [14]. Plasmids used were 
pUC118 [15] and pDP31 [12]. For membrane preparations [16], 
cells were grown 6 h in 50 ml of glucose/minimal salts/2.5% 
LB/ampicillin then inoculated into 1 l glucose/minimal 
salts/25070 LB/ampicillin. ATPase was measured as described 
by Wise et al. [7]. 
2.2. Cloning and sequencing of  the uncD gene from strain 
MA12 
Chromosomal DNA from strain MA12 was prepared, 
digested with PstI and run on agarose gels. Slices corresponding 
to predicted DNA fragment sizes of 0.94 and 1.2 kb were excis- 
ed and the fragments were ligated into PstI-cut pUC 118. From 
the restriction map of the unc operon, we expected to obtain 
recombinants containing the promoter-proximal nd -distal 
halves of the uncD ~-subunit) gene. The ligation mixture was 
transformed into strain JMI09 on LB/ampicillin/Xgal/IPTG 
plates, and colorless transformants were grown up in LB/am- 
picillin. Dot hybridization was then carried out on 
nitrocellulose using DNA from 50/~1 alkali-lysed ceils. The 35S- 
labeled probe was a fragment containing the uncD ~-subunit) 
gene, labeled by the random-primed method [17]. For confir- 
mation that the desired clones were identified, restriction diges- 
tions were carried out on plasmid minipreps. Double-stranded 
DNA sequencing was carried out by the chain termination 
method using a series of oligonucleotide 20-mers covering the 
uncO gene. 
2.3. Construction of  a plasmid for expression of  aurovertin 
resistance 
Plasmid pMA12.A (pUCll8 containing the 1.2 kb Pstl frag- 
ment corresponding to the promoter-distal half of the uncD 
gene with the aurovertin resistance mutation in it) was digested 
with XmalIl and KpnI and the resultant 1 kb fragment was 
isolated from an agarose gel. Plasmid pDP31 was digested with 
HindIII-XmaIII yielding a 1.4 kb fragment containing the nor- 
mal promoter-proximal half of uncD. Both fragments were 
mixed with HindIII/KpnI-digested pUCll8, ligated, and 
transformed into JM109 on LB/ampicillin/Xgal/IPTG plates. 
Plasmids were prepared from colorless transformants, checked 
by restriction digestion and sequenced to confirm that the 
aurovertin-resistance mutation was present. One plasmid con- 
taining the mutation was named pMA12.R. 
3. RESULTS 
The  entire uncD (f l -subunit) gene f rom strain 
MA12 was sequenced and was found  to conta in  
only  a single base change.  Codon 399 (normal ly  
CGC)  was changed to CAC,  result ing in the amino  
acid change R398 --, H .  
In  order  to conf i rm that this mutat ion  was 
respons ib le  for  aurover t in  resistance, we moved 
the mutat ion  f rom the init ial c lone (pMA12.A)  in- 
to p lasmid pDP31 which expresses the normal  
uncD gene [12], y ielding p lasmid pMA12.R  as 
descr ibed in sect ion 2. We t rans formed strain 
AN818 with both  pMA12.R  and pDP31.  Strain 
AN818 ( recA) ,  carry ing the mutat ion  G214R in fl- 
subuni t ,  is complete ly  defect ive in F1 -ATPase  
assembly  and shows zero membrane-bound AT-  
Pase act iv i ty [11,16]. For  fur ther  compar i son  we 
also used strain MA12 and the hap lo id  normal  
strain AN1339.  The results o f  membrane  ATPase  
and growth  assays o f  these four  strains are shown 
in table 1. The  mutat ion  ~?-R398H, when expressed 
f rom p lasmid pMA12.R ,  gave smal l  reduct ion  o f  
g rowth  yield on l imit ing glucose and also o f  
g rowth  on succinate plates. Membrane  ATPase  ac- 
Table 1 
Membrane ATPase and growth characteristics 
Strain Genotype Membrane- Growth yield Growth on 
ATPase on limiting succinate b 
(gmol/min glucose a 
per mg) (ODsa0) 
pDP31/AN818 unc + 2.4 0.78 + + + 
pMA12.R/AN818 ~'-R398H 1.7 0.72 + + 
pUC118/AN818 unc- 0 0.42 - 
MA12 B-R398H N.D. c 0.89 + + + 
AN1339 unc ÷ N.D. c 0.88 + + + 
a Growth yield on 3 mM glucose. Ampicillin (50,ug/ml) was included in 
medium for plasmid-bearing strains 
b Succinate plates 
¢ N.D., not determined 
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Table 2 
Inhibition of membrane ATPase by aurovertin 
Strain % ATPase activity 
pH 6.0 a pH 8.5 a 
No auro- 10/zM No auro- 10 #M 
vertin aurovertin vertin aurovertin 
pDP31/AN818 100 18 100 5 
pMA12.R/AN818 100 90 100 98 
a The pH 6.0 assay done in 50 mM succinate-Tris buffer; the 
pH 8.5 assay done in 50 mM Tris-SO4 buffer 
tivity was slightly-reduced ascompared to the con- 
trol (pDP31/AN818). Thus, under these 
conditions the mutation conferred a slight Unc 
phenotype, although this was not evident in the 
haploid strain MA12. 
Table 2 shows membrane ATPase assays in the 
presence and absence of aurovertin. From the data 
it is evident hat the mutation R398H/~-subunit is 
sufficient to confer aurovertin resistance on 
membrane-bound F1-ATPase. When aurovertin 
inhibition of membrane ATPase was measured at 
pH 6.0 vs pH 8.5 (table 2), little difference was 
seen in the mutant. Consistent with previous data 
on inhibition of cell growth at different pH [3], 
aurovertin was slightly less inhibitory toward nor- 
mal F~-ATPase at the lower pH. 
4. DISCUSSION 
Our results suggest hat residue R398 is part of 
the aurovertin-binding site in the normal F~ /5- 
subunit. The mutation R398H prevents aurovertin 
binding to the ~'-subunit and F1-ATPase [3,4,10], 
but does not significantly affect F~-ATPase activi- 
ty, oxidative phosphorylation, or the ability of ~- 
subunit to reconstitute with normal c~-, 7- and e- 
subunits to form an active ATPase [3,10]. 
If the charge of residue R398 were important in 
aurovertin binding, the replacement of arginine by 
histidine might have been expected to prevent 
binding at pH 8.5, but to be less effective at pH 
6.0. This was not the case. Thus, other factors such 
as bulk, stereochemistry or local environment 
changes might be invoked to explain the effect of 
the mutation. One possibility is that the R398 pK 
is shifted toward a less alkaline value due to a 
peculiar amino acid environment. This explanation 
is plausible as R398 is close to two other arginine 
residues, R392 and R394. 
Our results also have important consequences 
for the location of the catalytic nucleotide-binding 
domain in E. coli F1 g-subunit. It has been 
demonstrated that binding of ADP and aurovertin 
or of ATP and aurovertin may occur 
simultaneously to the isolated g-subunit of E. coli 
[4,18]. Also it is known that aurovertin inhibits E. 
coli F1 in an uneompetitive manner [19]. Previous- 
ly it has been suggested [20] that the catalytic 
nucleotide-binding domain of ~osubunit extends 
from residues 140-335 approximately. The exact 
limits of the sequence ncompassing this domain 
are, of course, speculative. The data presented 
here show that the region of sequence around 
residue 398 cannot be part of the nucleotide- 
binding domain. 
Finally it is interesting to note that the residue 
equivalent to E. coli F1 d-398 is usually, but not 
always, arginine in other species. Out of 21 species 
for which the sequence is currently known, 
arginine is present at this position in 18. Notably, 
this residue is phenylalanine in thermophilic 
bacterium PS3 [21] and PS3 F~ is known to be 
aurovertin insensitive [22]. 
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